The first five-year cumulative revenue (2017-2021) is projected to be US$ 1,946.0 Mn, which is expected to increase rather moderately over the latter part of the five-year forecast period. According to report, the glycated hemoglobin testing market is projected to reach a value of over US$ 650 Mn in 2026 at a CAGR of 8.6% over the forecast period.
